Tomonari Koike Selected Research

Coronary Artery Disease (Coronary Atherosclerosis)

1/2020	Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits.
1/2019	Identification of novel serum markers for the progression of coronary atherosclerosis in WHHLMI rabbits, an animal model of familial hypercholesterolemia.
3/2018	Ameliorating effects of D-47, a newly developed compound, on lipid metabolism in an animal model of familial hypercholesterolemia (WHHLMI rabbits).
11/2016	High susceptibility of atherosclerotic coronary arteries to the onset of vasospasm and angina pectoris-like symptoms due to coronary spasm in WHHLMI rabbits.
10/2015	Lipidomic analysis of plasma lipoprotein fractions in myocardial infarction-prone rabbits.
1/2015	High-fructose and high-fat diet-induced insulin resistance enhances atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
2/2013	Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.
11/2009	Human C-reactive protein does not promote atherosclerosis in transgenic rabbits.
8/2007	Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tomonari Koike Research Topics

Disease

17	Atherosclerosis 01/2021 - 06/2004
9	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 08/2007
7	Myocardial Infarction 01/2020 - 08/2007
6	Hypercholesterolemia 01/2020 - 02/2004
5	Hyperlipidemias (Hyperlipidemia) 12/2020 - 02/2004
5	Insulin Resistance 01/2015 - 02/2004
4	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 11/2013
3	Hypertriglyceridemia 01/2021 - 02/2004
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 11/2013
2	Inflammation (Inflammations) 12/2020 - 01/2020
2	Atherosclerotic Plaque (Atheroma) 05/2017 - 01/2014
2	Spasm (Spasms) 11/2016 - 11/2013
2	Aneurysm (Aneurysms) 12/2008 - 04/2006
2	Osteoarthritis 10/2004 - 10/2004
2	Rheumatoid Arthritis 10/2004 - 10/2004
1	Acute Coronary Syndrome 01/2022
1	Non-alcoholic Fatty Liver Disease 12/2020
1	Fatty Liver 12/2020
1	Vascular Remodeling 05/2017
1	Dyslipidemias (Dyslipidemia) 10/2015
1	Body Weight (Weight, Body) 01/2015
1	Glucose Intolerance 01/2015
1	Coronary Stenosis (Coronary Artery Stenosis) 01/2014
1	Thrombosis (Thrombus) 11/2013
1	Hypertension (High Blood Pressure) 11/2010
1	Vascular Diseases (Vascular Disease) 12/2008
1	Rupture 12/2008
1	Coronary Disease (Coronary Heart Disease) 08/2007
1	Proteinuria 07/2007
1	Diabetic Nephropathies (Diabetic Nephropathy) 07/2007
1	Hypertrophy 07/2007
1	Kasabach-Merritt Syndrome 12/2005
1	Hemangioma (Angioma) 12/2005
1	Synovitis 10/2004
1	Arthritis (Polyarthritis) 10/2004

Drug/Important Bio-Agent (IBA)

15	CholesterolIBA 01/2022 - 02/2004
12	LipidsIBA 12/2020 - 02/2004
7	Lipoproteins (Lipoprotein)IBA 01/2022 - 06/2004
6	Matrix Metalloproteinases (MMPs)IBA 05/2017 - 10/2004
4	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 02/2004
4	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 03/2005 - 02/2004
3	phosphatidylethanolamineIBA 01/2020 - 01/2017
2	Apolipoprotein A-II (Apolipoprotein A2)IBA 01/2021 - 02/2013
2	FructoseIBA 12/2020 - 01/2015
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 11/2013
2	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2020 - 01/2019
2	CeramidesIBA 01/2020 - 01/2019
2	VLDL LipoproteinsIBA 01/2017 - 12/2009
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 11/2016 - 11/2013
2	Ergonovine (Ergometrine)IBA 11/2016 - 11/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2007 - 12/2005
2	Matrix Metalloproteinase 12IBA 04/2006 - 10/2004
2	Pancreatic Elastase (Elastase)IBA 10/2004 - 10/2004
2	CarrageenanIBA 10/2004 - 06/2004
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2020
1	Transaminases (Aminotransferases)IBA 12/2020
1	Glutathione (Reduced Glutathione)IBA 12/2020
1	CytokinesIBA 12/2020
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 12/2020
1	Alanine-glyoxylate transaminase (alanine-glyoxylate aminotransferase)IBA 12/2020
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2020
1	Omega-6 Fatty Acids (Omega 6 Fatty Acids)IBA 01/2020
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2020
1	pitavastatin (itavastatin)FDA Link 01/2020
1	AntioxidantsIBA 01/2020
1	PlasmalogensIBA 01/2020
1	DiglyceridesIBA 01/2019
1	Pyrrolidonecarboxylic Acid (Pyroglutamic Acid)IBA 01/2019
1	PlasminogenIBA 01/2019
1	isocitric acid (isocitrate)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	Citric Acid (Citrate)FDA LinkGeneric 01/2019
1	CalciumIBA 05/2017
1	Apolipoprotein B-100 (Apo B 100)IBA 01/2017
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2017
1	Probucol (Lorelco)FDA Link 01/2014
1	EnzymesIBA 11/2013
1	Phenobarbital (Luminal)FDA Link 11/2013
1	MyoglobinIBA 11/2013
1	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 11/2013
1	Fatty Acid-Binding ProteinsIBA 11/2013
1	Troponin IIBA 11/2013
1	ApolipoproteinsIBA 02/2013
1	HDL LipoproteinsIBA 02/2013
1	Messenger RNA (mRNA)IBA 01/2012
1	Nonesterified Fatty Acids (NEFA)IBA 11/2010
1	IDL Lipoproteins (Lipoprotein, IDL)IBA 12/2009
1	C-Reactive ProteinIBA 11/2009
1	EndotoxinsIBA 02/2009
1	oxidized low density lipoproteinIBA 08/2007
1	Lipoprotein(a)IBA 08/2007
1	Angiogenesis InhibitorsIBA 12/2005
1	Proteins (Proteins, Gene)FDA Link 10/2005
1	Triglycerides (Triacylglycerol)IBA 02/2005
1	LDL Receptors (LDL Receptor)IBA 02/2005
1	SolutionsIBA 10/2004
1	Sucrose (Saccharose)IBA 10/2004

Therapy/Procedure

3	Therapeutics 12/2020 - 02/2004
1	Intravenous Infusions 11/2013